Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SkyePharma reacquires rights to pain drug
Under an agreement announced in April 2005, SkyePharma has received $10 million to date from Mundipharma, primarily to fund the phase II clinical trials for DepoBupivacaine, an extended-release
Under an agreement announced in April 2005, SkyePharma has received $10 million to date from Mundipharma, primarily to fund the phase II clinical trials for DepoBupivacaine, an extended-release
The Committee on Medicinal Products for Human Use (CHMP)’s ruling was based on questions concerning characterization, manufacturing and control and biosimilarity that have not yet been resolved to
In the first agreement, Medivir has outlicensed its preclinical HIV protease inhibitor project and, in the second agreement, provided a license for the MIV-210 polymerase inhibitor compound for
DG051 is a novel small-molecule inhibitor of leukotriene A4 hydrolase (LTA4H), the protein made by one of the genes in the leukotriene pathway DeCode has linked to risk
Transdrug is a treatment based on nanotechnology developed by BioAlliance Pharma. It allows intracellular drug targeting to optimize drug efficacy and patient tolerance. Doxorubicin Transdrug couples this technology
The committee also said that girls as young as nine should receive the vaccine at the discretion of doctors. Gardasil is designed to prevent the majority of human
The trial is being initiated following FDA and central institutional review board (IRB) approval of the trial protocol. The study builds on the observation of prolonged stable disease
Cipher’s Cip-Tramadol ER new drug application (NDA) contains data from six completed pharmacokinetic studies and five phase III studies with three of these providing pivotal efficacy data and
In addition to milestone and royalty payments to be paid to Nabi Biopharmaceuticals, Kedrion will assume development costs for the product candidate in both Europe and the US
Under the terms of the agreement, KineMed will apply its proprietary technologies to find alternative applications for discontinued compounds formerly in Organon’s clinical-stage pipeline. Once therapeutic utility is